Home » Authors » Anette Breindl

Articles by Anette Breindl

As One Large-Scale Project Begins, Another Called For

Dec. 22, 2005

By Anette Breindl

Cloning Paper To Be Retracted After Ethics, Data Questioned

Dec. 19, 2005

By Anette Breindl

Cloning Paper To Be Retracted After Ethics, Data Questioned

Dec. 19, 2005

By Anette Breindl

Antibody Fragment Serves As Surprise Anthrax Prophylaxis

Dec. 12, 2005

By Anette Breindl

Antibody Fragment Serves As Surprise Anthrax Prophylaxis

Dec. 12, 2005

By Anette Breindl

Synergistic With Velcade, NPI-0052 Heading To Clinic

Dec. 9, 2005

By Anette Breindl

Synergistic With Velcade, NPI-0052 Heading To Clinic

Dec. 9, 2005

By Anette Breindl

DNA-Methylating Enzyme Set To Become Biotech Workhorse

Dec. 5, 2005

By Anette Breindl

DNA-Methylating Enzyme Set To Become Biotech Workhorse

Dec. 5, 2005

By Anette Breindl

Something Old, Something New In Anxiolytics Research

Nov. 28, 2005

By Anette Breindl

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 6, 2025
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space
BioWorld
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could...
GLP-1 receptor agonists continue their global victory tour
BioWorld
2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their...
AI drives financings, approvals for APAC med-tech in 2024
BioWorld MedTech
AI pulled in major financings and approvals for Asia med-techs in 2024 as Asia Pacific countries played to individual strengths to maximize AI’s applications in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.